🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The COherence of Scatter Identification and Exclusion Algorithm Study

Recruitingn/aAges 18 Years - anyAllInstitute of Cancer Research, United Kingdom
NCT06975579 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040. NAFLD is an unwanted side effect of common cancer therapies, such as chemotherapy. Ultrasound can detect NAFLD via measurement of the backscatter coefficient (BSC). It is an attractive technique because of its low cost and availability, potentially enabling earlier detection of NAFLD in a larger population through screening. This approach has shown promise in detecting NAFLD but is limited by variability in measurement due to several factors. Measurement of the BSC requires assumptions about the nature of the tissue being measured; if these assumptions are incorrect, they can lead to inaccurate BSC measurements. To improve accuracy, an algorithm (COSIE) was developed to quantify the suitability of tissue for BSC analysis. The

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Healthy Volunteers: * Healthy male or female adults (18 or above). * Volunteers must consider themselves fit and healthy. * RMH and/or ICR employees. Patients: * Patients undergoing liver MRI as part of clinical standard of care with evidence of steatosis on preceding MRI. * Aged 18 and above. Exclusion Criteria: Healthy Volunteers: * Volunteers that are under investigation or planning to consult their GP to seek investigation for an undiagnosed condition, particularly regarding pelvic or abdominal disease or injury. * Healthy volunteers who do not have an NHS number or who are not registered with a GP will be excluded. Patients: • Severe liver fibrosis (fibrosis stage F4) or severe cirrhosis.
💊

What it tests

  • Ultrasound image processing
📍

Where

1 site
The Royal Marsden Hospital
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy